Raphael Pharmaceutical (RAPH) Net Cash Flow (2020 - 2025)
Raphael Pharmaceutical (RAPH) reported Net Cash Flow of $42000.0 for Q4 2025, up 300.0% on a YoY basis from $10500.0 in Q4 2024, and up 347.06% sequentially from -$17000.0 in Q3 2025.
Raphael Pharmaceutical (RAPH) Net Cash Flow (2020 - 2025) Analysis & Trends
Raphael Pharmaceutical (RAPH) has 6 years of Net Cash Flow data on file, last reported at $42000.0 in Q4 2025.
- For the quarter ending Q4 2025, Net Cash Flow rose 300.0% year-over-year to $42000.0; the trailing twelve-month figure through Dec 2025 stood at $26000.0 (up 112.26% YoY), and the FY2025 full-year result was $26000.0, up 112.32% from the prior year.
- Net Cash Flow advanced to $42000.0 in Q4 2025, from -$17000.0 in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $208000.0 in Q2 2021 to a low of -$250000.0 in Q1 2023.
- A 5-year average of -$2450.0 and a median of -$19000.0 in 2024 frame the typical range for Net Cash Flow.
- Across the five-year window, Net Cash Flow soared 570.0% in 2023 and plunged 330.14% in 2024, its largest moves.
- Tracing RAPH's Net Cash Flow over 5 years: stood at $116000.0 in 2021, then soared by 68.1% to $195000.0 in 2022, then tumbled by 135.38% to -$69000.0 in 2023, then soared by 69.57% to -$21000.0 in 2024, then jumped by 300.0% to $42000.0 in 2025.
- Business Quant data shows RAPH's Net Cash Flow at $42000.0 in Q4 2025, -$17000.0 in Q3 2025, and -$30000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 202.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -526.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 711.50 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -277.40 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 461.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -446.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -112.00 Mn |
| 10 | Raphael Pharmaceutical | 27.37 Mn | 27.33 Mn | - | 42,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 42,000.00 |
| Dec 31, 2025 | 42,000.00 |
| Sep 30, 2025 | -17,000.00 |
| Sep 30, 2025 | -17,000.00 |
| Jun 30, 2025 | -30,000.00 |
| Jun 30, 2025 | -30,000.00 |
| Mar 31, 2025 | 31,000.00 |
| Mar 31, 2025 | 31,000.00 |
| Dec 31, 2024 | -21,000.00 |
| Dec 31, 2024 | -21,000.00 |
| Sep 30, 2024 | -80,000.00 |
| Sep 30, 2024 | -80,000.00 |
| Jun 30, 2024 | -168,000.00 |
| Jun 30, 2024 | -168,000.00 |
| Mar 31, 2024 | 57,000.00 |
| Mar 31, 2024 | 57,000.00 |
| Dec 31, 2023 | -69,000.00 |
| Dec 31, 2023 | -69,000.00 |
| Sep 30, 2023 | 188,000.00 |
| Sep 30, 2023 | 188,000.00 |